Excellent
Partially Aligned
Patient Risk:
Low
Summary
All three AI claims concern approval date/brand attribution and company association. The provided label excerpts confirm the brand name (NERLYNX) and active ingredient but do not include approval date or sponsor/manufacturer attribution; those two items therefore cannot be verified from the supplied label text.
Category Scores
Accurate Statements
The FDA-approved brand name for neratinib is Nerlynx.
The provided label excerpts are for NERLYNX (neratinib) tablets.
Unsupported Statements
Neratinib (brand name Nerlynx) received FDA approval on July 17, 2017.
The provided prescribing information excerpts do not include the FDA approval date.
Puma Biotechnology is the company associated with the branded version of neratinib (Nerlynx) in FDA approval information.
The provided prescribing information excerpts do not include sponsor/manufacturer/company attribution.
Contradictions
Important Omissions
For the claims about FDA approval date (July 17, 2017) and company attribution (Puma Biotechnology), the supplied label text does not contain the corresponding approval/sponsor details needed to evaluate them.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Low
The evaluated statements are administrative (approval date/brand name/company association) and do not make dosing, safety, contraindication, or usage claims.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Low |
Recommendation
Partially Aligned
Primary Issue
Two statements (FDA approval date and company association) are not verifiable from the supplied label excerpts.
Suggested Improvement
Limit claims to label-supported information from the provided excerpts (e.g., brand name NERLYNX for neratinib). If approval date and company attribution are needed, source them from the label sections that contain approval/sponsor details (not provided in the excerpts).